July 2023

July 25, 2023 - IGEM in the News

Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer

July 25, 2023 0 0 0

Final results of phase I study of MOv18 IgE in ovarian cancer published in Nature Communications MOv18 IgE found to be safe and well tolerated with evidence of anti-tumour activity observed London, 25 July 2023 – Epsilogen, a global leader in the...